Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study. (PubMed, Front Pharmacol) - Sep 23, 2026 - "The study included 38,479 primary-suspect reports with known age for crizotinib, entrectinib, brigatinib, lorlatinib, repotrectinib, cabozantinib, or ceritinib...The early reporting pattern favors close assessment soon after treatment initiation. FAERS signals remain hypothesis-generating and require confirmation in longitudinal patient-level data."
Adverse events • Journal • Oncology • Pediatrics • ALK • ROS1
|
|
Hao Zhong; Xingjun Huang; Yige Yu; Yingyu Yu; Yongjian Liu
|